Nkarta, Inc.
NASDAQ:NKTXBiotechnology
Healthcare
$1.12 +3.41%
+$0.09 today
- Market cap
- $80.22M
- Beta
- 0.90
- P/E (TTM)
- -2.0
- EPS (TTM)
- -$1.35
52W Low $1.63High $3.65
Volume 0.66M
Average 0.75M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$88.70M
FY 2025 · Annual
Investing Cash Flow
$100.32M
FY 2025 · Annual
Financing Cash Flow
$141,000.00
FY 2025 · Annual
-99.9% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (86.08M) | (113.84M) | (117.5M) | (108.79M) | (104.08M) |
| Depreciation & Amortization | 1.76M | 2.64M | 5.87M | 2.24M | 4.61M |
| Deferred Income Tax | 3.24M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 14.46M | 16.86M | 17.2M | 16.73M | 8.56M |
| Change in Working Capital | (1.64M) | 33.74M | 10.93M | (12.16M) | (435K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.79M | 2.76M | 4.22M | (4.47M) | 2.46M |
| Other Working Capital | (4.44M) | 30.98M | 6.7M | (7.69M) | (2.9M) |
| Other Non-Cash Items | 337K | 3.61M | (2.65M) | 2.29M | 2.65M |
| Operating Cash Flow | (67.93M) | (57M) | (86.16M) | (99.7M) | (88.7M) |
| Capital Expenditures | (5.03M) | (47.11M) | (28.15M) | (4.41M) | (1.21M) |
| Acquisitions (Net) | (37.56K) | 137.58K | 0 | 0 | 0 |
| Purchases of Investments | (227.28M) | (385.89M) | (260.23M) | (406.38M) | (238.57M) |
| Sales of Investments | 264.84M | 248.31M | 367.4M | 281.23M | 340.09M |
| Other Investing Activities | 37.56K | (137.58K) | 0 | 0 | 0 |
| Investing Cash Flow | 32.53M | (184.69M) | 79.02M | (129.56M) | 100.32M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 1.2M | 217.17M | 691K | 225.07M | 141K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 1.84M | 0 | 1.01M | 0 |
| Financing Cash Flow | 1.2M | 219.01M | 691K | 226.08M | 141K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (34.19M) | (22.68M) | (6.45M) | (3.17M) | 11.76M |
| Free Cash Flow | (72.95M) | (104.11M) | (114.31M) | (104.11M) | (89.91M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$104.1M
+ D&A$4.6M
+ Stock-Based Comp$8.6M
+ Deferred Tax$0
- Working Capital-$435.0K
+ Other Non-Cash$2.6M
= Operating Cash Flow-$88.7M
- Capex-$1.2M
= Free Cash Flow-$89.9M
Analysis
FY2025 free cash flow is -$89.9M. FCF conversion is 86.4% of net income. Operating cash flow was -$88.7M, with capex of -$1.2M. The largest bridge item is Stock-Based Comp at $8.6M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 9, 2026 | |
| 8-K | Current report | Nov 6, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| 8-K | Current report | Aug 10, 2026 |
Does NKTX generate free cash flow?
Nkarta, Inc. (NKTX) generated -$89.91M of free cash flow in fiscal 2025.
How much operating cash flow does NKTX produce?
Operating cash flow was -$88.70M, before capital expenditures of $1.21M.
Continue the stock analysis
Jump to another research area for this company.